DBV expects cash runway into Q3 2027 as it advances sequential FDA reviews for VIASKIN Peanut BLAs

DBV Technologies Q3 2026 earnings: BLA filing progress, FDA inspection readiness, manufacturing risks, and cash runway into 2027.

CryptoAlerta — análise de criptomoedas e mercado em tempo real